HC Wainwright reissued their buy rating on shares of BioCardia (NASDAQ:BCDA – Free Report) in a report released on Monday morning, Benzinga reports. HC Wainwright currently has a $25.00 target price on the stock.
BioCardia Trading Down 1.7 %
NASDAQ BCDA opened at $2.33 on Monday. The company has a market cap of $4.95 million, a P/E ratio of -0.43 and a beta of 1.26. The company has a fifty day simple moving average of $2.68 and a 200 day simple moving average of $3.58. BioCardia has a 12-month low of $1.96 and a 12-month high of $23.25.
BioCardia (NASDAQ:BCDA – Get Free Report) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.78). Sell-side analysts predict that BioCardia will post -5.06 EPS for the current year.
About BioCardia
BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.
Featured Stories
- Five stocks we like better than BioCardia
- The Risks of Owning Bonds
- Microsoft Can Hit New All-Time Highs This Year – Here’s Why
- When to Sell a Stock for Profit or Loss
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- Canadian Penny Stocks: Can They Make You Rich?
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with MarketBeat.com's FREE daily email newsletter.
